Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/24723Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Milionis, H. J. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:43:06Z | - |
| dc.date.available | 2015-11-24T19:43:06Z | - |
| dc.identifier.issn | 1262-3636 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/24723 | - |
| dc.rights | Default Licence | - |
| dc.subject | Antineoplastic Agents, Hormonal/adverse effects | en |
| dc.subject | Antineoplastic Combined Chemotherapy Protocols/therapeutic use | en |
| dc.subject | Blood Glucose/metabolism | en |
| dc.subject | Breast Neoplasms/*drug therapy/surgery | en |
| dc.subject | Cholesterol, HDL/blood | en |
| dc.subject | *Diabetes Complications | en |
| dc.subject | Diabetes Mellitus/blood | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Hypertriglyceridemia/*chemically induced | en |
| dc.subject | Lipoprotein(a)/blood | en |
| dc.subject | Middle Aged | en |
| dc.subject | Phenotype | en |
| dc.subject | Tamoxifen/*adverse effects | en |
| dc.subject | Triglycerides/blood | en |
| dc.title | Tamoxifen-induced hypertriglyceridemia in association with diabetes mellitus | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/11353883 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2001 | - |
| heal.abstract | Several pharmacological agents are associated with hyperlipidemia. Tamoxifen is an example of a drug-induced increase of serum triglyceride levels. However, there are only scarce reports on how inborn errors in lipid metabolism as well as secondary dyslipidemias, including diabetes mellitus, influence the hypertriglyceridemic effect of tamoxifen. Herein, we describe a case of a breast cancer patient receiving tamoxifen who presented with remarkable hypertriglyceridemia in the context of diabetes mellitus. We also provide a brief review of the relevant literature and discuss the mechanisms underlying the pathogenesis of hypertriglyceridemia related to tamoxifen. | en |
| heal.journalName | Diabetes & Metabolism | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
